Read More Pharma Industry News Merck’s once-daily DOR/ISL HIV therapy delivers sustained viral control and weight stability in Phase 3 results Discover how Merck’s DOR/ISL HIV therapy preserves viral suppression and metabolic stability, signaling a new era in patient-centered HIV care. bySoujanya RaviOctober 15, 2025